Twice-Yearly Depemokimab Maintained Asthma Control After Switching From Mepolizumab or Benralizumab, but Did Not Meet Formal Noninferiority for Exacerbations
Posted inAllergy & Immunology news Respiratory

Twice-Yearly Depemokimab Maintained Asthma Control After Switching From Mepolizumab or Benralizumab, but Did Not Meet Formal Noninferiority for Exacerbations

In the phase 3A NIMBLE trial, switching biologic-responsive severe asthma patients to twice-yearly depemokimab preserved overall control and showed comparable safety, but formal noninferiority versus continued mepolizumab or benralizumab for exacerbations was not achieved.
Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care
Posted inAllergy & Immunology Clinical Updates news Respiratory

Mapping Multimorbidity in Severe Asthma: Defining Replicable Phenotypes to Optimize Personalized Care

This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocating for a holistic approach to complex patient management.